Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

AbCellera Biologics (ABCL) Receives a Buy from Truist Financial

Tipranks - Tipranks - Tue Apr 7, 6:42AM CDT

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on AbCellera Biologics today and set a price target of $3.52.

Easter Sale - 70% Off TipRanks

According to TipRanks, Devarakonda is a 5-star analyst with an average return of 15.1% and a 51.95% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Cytokinetics, and Eli Lilly & Co.

AbCellera Biologics has an analyst consensus of Strong Buy, with a price target consensus of $5.84.

See today’s best-performing stocks on TipRanks >>

Based on AbCellera Biologics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $44.85 million and a GAAP net loss of $8.95 million. In comparison, last year the company earned a revenue of $5.05 million and had a GAAP net loss of $34.21 million

Read More on ABCL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).